C1 inhibitor deficiency in a patient with rheumatoid arthritis--increased risk of adverse effects of penicillamine?
We report the coincidence of hereditary angioedema and rheumatoid arthritis in a male patient and in his father. During treatment with D-penicillamine the patient developed a transient lupus-like disorder with glomerulonephritis that resolved when D-penicillamine was discontinued. He later was diagnosed with malignant lymphoma. Impaired classical complement pathway function could have contributed to development of the drug reaction.
Sturfelt
G
G
Department of Rheumatology, Lund University Hospital, Sweden.
Rydgren
L
L
Truedsson
L
L
Alm
P
P
Sjöholm
A G
AG
D000799:Angioedema / Q000150:complications / Q000235:genetics; D001172:Arthritis, Rheumatoid / Q000097:blood* / Q000150:complications / Q000188:drug therapy*; D002648:Child; D003174:Complement C1 Inactivator Proteins / Q000172:deficiency*; D005921:Glomerulonephritis / Q000139:chemically induced / Q000473:pathology; D006801:Humans; D008180:Lupus Erythematosus, Systemic / Q000139:chemically induced; D008297:Male; D010396:Penicillamine / Q000009:adverse effects* / Q000627:therapeutic use; D012307:Risk Factors
D003174:Complement C1 Inactivator Proteins; D010396:Penicillamine